Observational studyClinical immunology (Orlando, Fla.)2021
Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.
Observational study in Clinical immunology (Orlando, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Association between Guillain-Barré syndrome and SARS-CoV-2 virus infection, including the impact of COVID-19 vaccination in the context of the development and general clinical characteristics of the disease.Journal of neurovirology · 2025Pooled it
- Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.BMC neurology · 2023Pooled it
- Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review.Immunologic research · 2022Pooled it
- Adverse events following SARS-CoV-2 mRNA vaccination in norwegian adolescents.Scientific reports · 2026Article
- Review
- Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model.Archives of toxicology · 2025Article
- COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions.AIMS neuroscience · 2025Review
- Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.Vaccines · 2024Review
- Cholera and COVID-19 pandemic prevention in multiple hotspot districts of Uganda: vaccine coverage, adverse events following immunization and WASH conditions survey.BMC infectious diseases · 2023Article
- Neurological Disorders following COVID-19 Vaccination.Vaccines · 2023Review
- COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.Immunity, inflammation and disease · 2023Review
- Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis.Clinical and experimental vaccine research · 2023Article
- Case Series of Acute Peripheral Neuropathies in Individuals Who Received COVID-19 Vaccination.Medicina (Kaunas, Lithuania) · 2023Article
- Is there a causal nexus between COVID-19 infection, COVID-19 vaccination, and Guillain-Barré syndrome?European journal of medical research · 2023Review
- Guillain-Barre syndrome following COVID-19 vaccines: A review of literature.Frontiers in immunology · 2023Review
- Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: Case report and scope review.Human vaccines & immunotherapeutics · 2022Review
- Miller Fisher syndrome after Pfizer BioNTech vaccine booster responsive to intravenous Ig treatment.BMJ case reports · 2022Article
- Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program.Journal of clinical immunology · 2022Observational
- [NEUROLOGICAL MANIFESTATIONS ASSOCIATED WITH COVID-19 VACCINE].Neurologia (Barcelona, Spain) · 2022Article
- Seizures following COVID-19 vaccination in Mexico: A nationwide observational study.Epilepsia · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worldwide. A causal link between mRNA vaccines and GBS has not been previously evaluated. We analyzed a cohort of 3,890,250 Hispanic/Latinx recipients of the BNT162b2 mRNA vaccine (613,780 of whom had already received both doses) for incident GBS occurring within 30 days from vaccine administration. Seven cases of GBS were detected among first-dose recipients, for an observed incidence of 0.18/100,000 administered doses during the prespecified timeframe of 30 days. No cases were reported after second-dose administration. Our data suggest that, among recipients of the BNT162b2 mRNA vaccine, GBS may occur at the expected community-based rate; however, this should be taken with caution as the current incidence of GBS among the unvaccinated population against COVID-19 is still undetermined. We hope that this preliminary data will increase the public perception of safety toward mRNA-based vaccines and reduce vaccine hesitancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.